Clinical trial NCT02910375: Golimumab Dried Blood Spot Analysis
Official title: A Prospective Multi-centric Belgian Trial to Validate the Use of Golimumab Serum Level Analysis Using the Dried Blood Spot (DBS) Methodology
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Ulcerative Colitis
Keywords: golimumab
drug monitoring
home based care
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
Collaborators: name: General Hospital Groeninge
First posted: 2016-09-22
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This retrospective multi-centric Belgian prospective trial will involve 10 patients initiating or under maintenance subcutaneous golimumab therapy for moderate-to-severe colitis at the University Hospitals Leuven (Leuven, Belgium) or AZ Groeninge (Kortrijk, Belgium)

Patients will (have) receive(d) standard induction therapy with golimumab 200mg at week 0, and golimumab 100mg at week 2. Maintenance therapy will (have) start(ed) at week 6, with 50 or 100mg of golimumab every 4 weeks, depending on body weight (50mg every 4 weeks for patients with a body weight of less than 80kg, and 100mg for the others)

Patients will come to the hospital for clinical evaluation, blood sampling and golimumab administration following daily clinical practice. The patients will be requested to perform several dry blood spot analyses at home.

Detailed description: BLOOD SAMPLING:

Blood samples are collected using two sampling methods at different time points (indicated on the timeline above); DBS sampling (max 39 samples/patient) and venous blood sampling (max 13 samples/patient). Venous blood sampling will be performed during a standard outpatient clinic in one of the participating centres, and forwarded to the Laboratory for Therapeutic and Diagnostic Antibodies in Leuven for further analyses. DBS samples will be send directly to the Laboratory for Therapeutic and Diagnostic Antibodies in Leuven through classical mailing.

DBS sampling will be performed by the patient during the outpatient clinic (at same moment as venous punctures, max 13 samples/patient) and at home for the intermediate values (max 26 samples/patient). Patients will be taught how to perform a finger prick during the outpatient clinic. A conversion factor will be defined. Determination of concentration-time profile and exposure of golimumab in the individual patients will be performed by intensive sampling for 3 to 4.5 months. Time point of max concentration, intermediate concentration, and trough concentration will be determined in each patient.

Note: A similar procedure will be adopted to measure free anti-golimumab antibody concentrations on the DBS using a drug sensitive assay. Free anti-golimumab antibody concentrations will be measured when the serum golimumab concentration is below limit of quantification.

MEASUREMENT OF GOLIMUMAB AND ANTI-GOLIMUMAB ANTIBODY CONCENTRATIONS:

Golimumab concentrations will be measured using a sandwich type ELISA, in which golimumab is captured between an immobilized monoclonal antibody towards golimumab (MA-GLM) 171D8 and an added horseradish peroxidase (HRP)-labeled MA-GLM159B8. The assay was developed and validated, analytically (external and internal) and clinically, as described by Detrez et al. Golimumab concentrations will be measured on every sample.

Free anti-golimumab antibody concentrations will be measured using a drug sensitive assay. Total anti-golimumab antibody concentrations will be measured using a drug tolerant assay. Development and validation (analytical + clinical) of these assays is described by Detrez et al. Total anti-golimumab antibody concentrations will be measured on every venous sample. Free anti-golimumab antibody concentrations will be measured when the serum golimumab concentration is below limit of quantification on both venous sample and DBS sample (based on adalimumab serum concentrations measured in by our laboratory, we expect that 11% of samples measured within the first year of treatment have an undetectable golimumab concentration).

BASELINE CHARACTERISTICS:

* Baseline characteristics will include: sex, age at diagnosis, weight, body mass index, disease extent, smoking status (never, ex, active), primary sclerosing cholangitis, haemoglobin, serum albumin, and C-reactive protein
* Previous medical characteristics will include previous use of mesalamine, steroids, immunosuppressive agents, ciclosporin, infliximab, adalimumab, vedolizumab, ...
* Current medical characteristics will include use of mesalamine, use of steroids (dosing, duration since initiation), use of immunosuppressive agents (dosing, duration since initiation), use of golimumab (dosing, duration since initiation, last dose), ...

QUESTIONNAIRE REGARDING PATIENT FRIENDLINESS:

• At the end of the study the participants will be requested to fill out a questionnaire regarding the patient friendliness of the dried blood spot (DBS) methodology

Eligibility criteria: Inclusion Criteria:

* Age at least 18 at moment of inclusion
* Established diagnosis of ulcerative colitis (UC)
* Patients under golimumab therapy for moderate-to-severe colitis, including minimally 3 patients who will initiate golimumab therapy

Exclusion Criteria:

* Subjects with Crohn's disease, or IBD type unclassified
* Subjects who underwent a subtotal colectomy or proctocolectomy

Primary outcomes:
measure: Comparison of golimumab serum sample through venous puncture and dried blood spot analysis
timeFrame: During 4.5 months for golimumab starters and 3.0 months for patients under golimumab maintenance therapy
Secondary outcomes:
measure: Area under the curve of golimumab exposure during induction therapy
timeFrame: 1.5 months
measure: Area under the curve of golimumab exposure during maintenance therapy
timeFrame: 3.0 months
measure: Maximum golimumab serum concentration during induction therapy
timeFrame: 1.5 months
measure: Maximum golimumab serum concentration during maintenance therapy
timeFrame: 3.0 months
measure: Patient perception question 1: The information I received from my physician and colleagues regarding dried blood spot analyses was adequate
timeFrame: After 4.5 months for golimumab starters and after 3.0 months for patients under golimumab maintenance therapy
measure: Patient perception question 2: I had fluent access to further information on all aspects of the dried blood spot analysis
timeFrame: After 4.5 months for golimumab starters and after 3.0 months for patients under golimumab maintenance therapy
measure: Patient perception question 3: With the provided tools it was easy to get a blood spot on the paper.
timeFrame: After 4.5 months for golimumab starters and after 3.0 months for patients under golimumab maintenance therapy
measure: Patient perception question 4: With the provided tools it was easy to send/bring the paper with the dried blood spot to the physician/lab
timeFrame: After 4.5 months for golimumab starters and after 3.0 months for patients under golimumab maintenance therapy
measure: Patient perception question 5: I prefer to perform the dried blood spot at home than to go to the hospital for venous sampling
timeFrame: After 4.5 months for golimumab starters and after 3.0 months for patients under golimumab maintenance therapy
measure: Patient perception question 6: In general this dried blood spot system is user friendly
timeFrame: After 4.5 months for golimumab starters and after 3.0 months for patients under golimumab maintenance therapy
Other outcomes:
Locations:
city: Belgium
country: Belgium
facility: AZ Groeninge
state: Kortrijk
city: Leuven
country: Belgium
facility: UZ Leuven
Study officials:
affiliation: Universitaire Ziekenhuizen KU Leuven
name: Marc Ferrante, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Detrez I, Schops G, Lefrere J, Tops S, Van Assche G, Vermeire S, Van Moerkercke W, Ferrante M, Gils A. Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information. AAPS J. 2018 Dec 18;21(1):10. doi: 10.1208/s12248-018-0282-x.